Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 18775330 
Casar B, Pinto A, Crespo P (2008) Essential role of ERK dimers in the activation of cytoplasmic but not nuclear substrates by ERK-scaffold complexes. Mol Cell 31, 708-21 18775330
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S505-p - cPLA2 (human)
Orthologous residues
cPLA2 (human): S505‑p, cPLA2 (mouse): S505‑p, cPLA2 (rat): S505‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
EGF DAGLBETA (human) no effect upon treatment-induced increase
EGF IQGAP1 (human) no effect upon treatment-induced increase
EGF KSR (human) no effect upon treatment-induced increase
EGF ARRB1 (human) no effect upon treatment-induced increase
EGF ARRB2 (human) no effect upon treatment-induced increase
EGF PXN iso2 (human) no effect upon treatment-induced increase
EGF IL17RD (human) no effect upon treatment-induced increase
EGF increase
EGF DAGLBETA (human) no effect upon treatment-induced increase
EGF IQGAP1 (human) no effect upon treatment-induced increase
EGF KSR (human) no effect upon treatment-induced increase
EGF ARRB1 (human) no effect upon treatment-induced increase
EGF ARRB2 (human) no effect upon treatment-induced increase
EGF PXN iso2 (human) no effect upon treatment-induced increase
EGF IL17RD (human) no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activity, induced, enzymatic activity, induced
 Effect of modification (process):  cell growth, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
KSR (human) Induces molecular association, regulation cell growth, altered electrophoretic visualization, co-immunoprecipitation
 Comments:  PLA2 binding to KSR1 is mediated by ERK .

S383-p - ELK1 (human)
Orthologous residues
ELK1 (human): S383‑p, ELK1 (mouse): S384‑p, ELK1 (rat): S382‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
EGF DAGLBETA (human) no effect upon treatment-induced increase
EGF IQGAP1 (human) no effect upon treatment-induced increase
EGF KSR (human) no effect upon treatment-induced increase
EGF ARRB1 (human) no effect upon treatment-induced increase
EGF ARRB2 (human) no effect upon treatment-induced increase
EGF PXN iso2 (human) no effect upon treatment-induced increase
EGF IL17RD (human) no effect upon treatment-induced increase

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HRas (human) increase
EGF increase
EGF DAGLBETA (human) no effect upon treatment-induced increase
EGF IQGAP1 (human) no effect upon treatment-induced increase
EGF KSR (human) no effect upon treatment-induced increase
EGF ARRB1 (human) no effect upon treatment-induced increase
EGF ARRB2 (human) no effect upon treatment-induced increase
EGF PXN iso2 (human) no effect upon treatment-induced increase
EGF IL17RD (human) no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activity, induced, enzymatic activity, induced, protein conformation
 Effect of modification (process):  cell growth, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
KSR (human) Induces molecular association, regulation cell growth, altered electrophoretic visualization, co-immunoprecipitation
KSR (human) Induces molecular association, regulation cell growth, altered electrophoretic visualization, co-immunoprecipitation
 Comments:  ERK dimers and and scafolds activate cytoplasmic substrates; PLA2 binding to KSR1 is mediated by ERK .

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HRas (human) increase
EGF increase
EGF DAGLBETA (human) no effect upon treatment-induced increase
EGF IQGAP1 (human) no effect upon treatment-induced increase
EGF KSR (human) no effect upon treatment-induced increase
EGF ARRB1 (human) no effect upon treatment-induced increase
EGF ARRB2 (human) no effect upon treatment-induced increase
EGF PXN iso2 (human) no effect upon treatment-induced increase
EGF IL17RD (human) no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activity, induced, enzymatic activity, induced, protein conformation
 Effect of modification (process):  cell growth, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
KSR (human) Induces molecular association, regulation cell growth, altered electrophoretic visualization, co-immunoprecipitation
KSR (human) Induces molecular association, regulation cell growth, altered electrophoretic visualization, co-immunoprecipitation
 Comments:  ERK dimers and and scafolds activate cytoplasmic substrates; PLA2 binding to KSR1 is mediated by ERK .

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HRas (human) increase
EGF increase
EGF DAGLBETA (human) no effect upon treatment-induced increase
EGF IQGAP1 (human) no effect upon treatment-induced increase
EGF KSR (human) no effect upon treatment-induced increase
EGF ARRB1 (human) no effect upon treatment-induced increase
EGF ARRB2 (human) no effect upon treatment-induced increase
EGF PXN iso2 (human) no effect upon treatment-induced increase
EGF IL17RD (human) no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activity, induced, enzymatic activity, induced, protein conformation
 Effect of modification (process):  cell growth, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
KSR (human) Induces molecular association, regulation cell growth, altered electrophoretic visualization, co-immunoprecipitation
KSR (human) Induces molecular association, regulation cell growth, altered electrophoretic visualization, co-immunoprecipitation
 Comments:  ERK dimers and and scafolds activate cytoplasmic substrates; PLA2 binding to KSR1 is mediated by ERK .

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
HRas (human) increase
EGF increase
EGF DAGLBETA (human) no effect upon treatment-induced increase
EGF IQGAP1 (human) no effect upon treatment-induced increase
EGF KSR (human) no effect upon treatment-induced increase
EGF ARRB1 (human) no effect upon treatment-induced increase
EGF ARRB2 (human) no effect upon treatment-induced increase
EGF PXN iso2 (human) no effect upon treatment-induced increase
EGF IL17RD (human) no effect upon treatment-induced increase
Downstream Regulation
 Effect of modification (function):  activity, induced, enzymatic activity, induced, protein conformation
 Effect of modification (process):  cell growth, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
KSR (human) Induces molecular association, regulation cell growth, altered electrophoretic visualization, co-immunoprecipitation
KSR (human) Induces molecular association, regulation cell growth, altered electrophoretic visualization, co-immunoprecipitation
 Comments:  ERK dimers and and scafolds activate cytoplasmic substrates; PLA2 binding to KSR1 is mediated by ERK .

T359-p - p90RSK (human)
Orthologous residues
p90RSK (human): T359‑p, p90RSK iso2 (human): T368‑p, p90RSK (mouse): T348‑p, p90RSK iso3 (mouse): , p90RSK (rat): T359‑p, p90RSK (chicken): T377‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines

S363-p - p90RSK (human)
Orthologous residues
p90RSK (human): S363‑p, p90RSK iso2 (human): S372‑p, p90RSK (mouse): S352‑p, p90RSK iso3 (mouse): , p90RSK (rat): S363‑p, p90RSK (chicken): S381‑p
Characterization
 Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.